SSI(SZ:002742)2022-08-25 16:00Financial Performance - The company's operating revenue for the first half of 2022 was ¥962,826,665.42, a decrease of 21.10% compared to ¥1,220,255,739.91 in the same period last year[24]. - The net loss attributable to shareholders was ¥40,738,537.48, representing a decline of 154.51% from a loss of ¥16,006,931.98 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was ¥-35,750,132.27, which is a 21.11% increase in loss compared to ¥-29,517,672.30 last year[24]. - The basic earnings per share were ¥-0.0943, down 154.18% from ¥-0.0371 in the same period last year[24]. - The company reported a significant increase in investment, with ¥81,061,612.29 in the reporting period, a change of 2,528.22% compared to the previous year[56]. - The company reported a total comprehensive loss of CNY 27,882,149.96 for the first half of 2022, compared to a loss of CNY 76,542,891.78 in the same period of 2021[163]. - The net profit for the first half of 2022 was a loss of CNY 27,882,149.96, compared to a loss of CNY 76,542,891.78 in the same period of 2021, indicating a narrowing of losses[163]. - The company reported a net loss of 24.1161 million yuan for 2022, indicating significant financial challenges[184]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,111,061,163.44, a decrease of 6.84% from ¥4,413,070,944.02 at the end of the previous year[24]. - The net assets attributable to shareholders decreased by 3.54% to ¥1,081,189,903.37 from ¥1,120,844,682.25 at the end of the previous year[24]. - The total liabilities decreased to ¥2,848,680,833.70 from ¥3,099,798,674.40 at the beginning of the year[151]. - The company reported a total debt of 65,000 million as of June 20, 2022, with a significant portion maturing on December 1, 2022[116]. - The company has a total approved guarantee amount of CNY 546.5 million during the reporting period, with actual guarantees amounting to CNY 41.8 million[119]. Cash Flow - The net cash flow from operating activities was ¥60,959,395.02, a slight decrease of 2.48% compared to ¥62,508,850.13 in the same period last year[24]. - The cash and cash equivalents net increase was ¥28.51 million, a decline of 64.69% compared to the previous year[46]. - The ending balance of cash and cash equivalents was ¥77,821,997.33, down 50.5% from ¥156,873,058.89 at the end of the first half of 2021[165]. - Total cash inflow from operating activities decreased to ¥843,293,629.32, down 31.7% from ¥1,235,645,619.69 in the first half of 2021[164]. - Cash outflow from operating activities also decreased to ¥782,334,234.30, a reduction of 33.3% compared to ¥1,173,136,769.56 in the previous year[164]. Business Segments - The company operates in two main business segments: construction materials and pharmaceuticals, with a leading position in ready-mixed concrete and additives in the construction materials sector[32]. - The pharmaceutical segment includes intermediates and active pharmaceutical ingredients, with key products such as procaine hydrochloride and cephalosporin intermediates, which hold a leading market position[33]. - The construction materials segment's revenue is primarily derived from ready-mixed concrete, concentrated in the Chongqing region, benefiting from the city's strategic economic position[35]. - The pharmaceutical manufacturing segment achieved profitability, contributing positively to the company's overall performance through enhanced management and market expansion efforts[38]. Market Conditions and Strategies - The company reported a loss in its main business due to severe market shocks in the construction materials sector, exacerbated by cash flow issues and strict environmental policies[37]. - The construction materials industry is closely tied to macroeconomic conditions, with demand expected to remain high due to ongoing infrastructure investments in Chongqing[36]. - The company has implemented various measures to mitigate losses, including internal management improvements and product price adjustments[38]. - The company plans to enhance its market expansion and diversification strategies to mitigate regional sales concentration risks[66]. - The company aims to improve its profitability by optimizing inventory management and enhancing accounts receivable turnover[68]. Environmental Compliance - The company strictly complies with various environmental protection laws and standards, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[77]. - The wastewater treatment plant operates within the limits of chemical oxygen demand (COD) at less than 100 mg/L and ammonia nitrogen at less than 15 mg/L[79]. - The company has implemented measures to ensure that emissions of particulate matter are below 30 mg/m3 and sulfuric acid mist below 5 mg/m3[79]. - The company has not reported any instances of exceeding pollution discharge standards[79]. Corporate Governance and Investor Relations - The company adheres to regulations for shareholder meetings, ensuring the rights of minority shareholders are protected through both in-person and online voting options[87]. - The company has established an investor hotline to enhance communication with minority investors, providing timely updates on company developments[87]. - The board secretary is responsible for information disclosure, ensuring compliance with regulatory standards and maintaining transparency with investors[87]. - The company has committed to fulfilling its promises regarding the initial public offering, with ongoing compliance monitored[89]. Future Outlook - The company plans to expand its market presence and invest in new product development in the upcoming quarters[170]. - The company aims to achieve a revenue growth target of 10% for the next fiscal year, driven by new product launches and market expansion efforts[170]. - Future guidance indicates a projected revenue growth of 10% for the next half-year, driven by increased demand and market expansion efforts[174].